Liraglutide is a clear, colorless solution. The dosage form is subcutaneous injection. After more than 10 years of research and development, Liraglutide has many functions such as promoting the regeneration of islet cells, lowering blood sugar, reducing weight and protecting the cardiovascular system. The brand name Victoza is used to treat type 2 diyabet, and the brand name Saxenda is used to treat chronic obesity. As a supplement to diet control and physical exercise. Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist, which has 97% amino acid sequence homology with human endogenous GChemicalbookLP-1 (7-37), and retains It has all the biological activities of GLP-1 and has GLP-1 receptor agonism. Through the expression of recombinant DNA in Saccharomyces cerevisiae, its molecular structure is only one amino acid difference from the natural GLP-1 molecule. The structure only modifies the following two parts of GLP-1: that is, the 34th lysine is replaced by arginine. Acid substitution, in addition to adding a glutamic acid-mediated 16-carbon palmitoyl fatty acid side chain on the 26th lysine.
1.It acts in a glucose-dependent manner, meaning it will stimulate insuli n secretion only when blood glucose levels are higher than normal, preventing ""overshoot"". Consequently, it shows negligible risk of hypoglycemia.
2.It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3.It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
4.It lowers blood triglyceride levels.
